[
  {
    "ts": null,
    "headline": "Why Bio-Techne (TECH) Shares Are Plunging Today",
    "summary": "Shares of life sciences company Bio-Techne (NASDAQ:TECH) fell 6.5% in the afternoon session after the company reported its fourth-quarter fiscal 2025 results, which included a significant net loss driven by a large impairment charge. The company posted a net loss of $17.68 million, a sharp reversal from the $40.59 million in net income recorded a year ago. This loss resulted from an $83.1 million impairment charge linked to the divestiture of its Exosome Diagnostics business. An impairment charg",
    "url": "https://finnhub.io/api/news?id=187532cbdbf4debe6bb82a768ed633bf118bfc386745f598d9975652abb8d22f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754500852,
      "headline": "Why Bio-Techne (TECH) Shares Are Plunging Today",
      "id": 136239385,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Shares of life sciences company Bio-Techne (NASDAQ:TECH) fell 6.5% in the afternoon session after the company reported its fourth-quarter fiscal 2025 results, which included a significant net loss driven by a large impairment charge. The company posted a net loss of $17.68 million, a sharp reversal from the $40.59 million in net income recorded a year ago. This loss resulted from an $83.1 million impairment charge linked to the divestiture of its Exosome Diagnostics business. An impairment charg",
      "url": "https://finnhub.io/api/news?id=187532cbdbf4debe6bb82a768ed633bf118bfc386745f598d9975652abb8d22f"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne (NASDAQ:TECH) Exceeds Q2 Expectations",
    "summary": "Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 3.5% year on year to $317 million. Its non-GAAP profit of $0.53 per share was 6.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=f712cc6b8c0aed267b17e57188c0e761cb0ec8cfe501a7efb0abadde680d4343",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754487089,
      "headline": "Bio-Techne (NASDAQ:TECH) Exceeds Q2 Expectations",
      "id": 136237597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 3.5% year on year to $317 million. Its non-GAAP profit of $0.53 per share was 6.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=f712cc6b8c0aed267b17e57188c0e761cb0ec8cfe501a7efb0abadde680d4343"
    }
  },
  {
    "ts": null,
    "headline": "Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings",
    "summary": "The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=0ca842306d09a80b48e22eae006dafe2f005372290151c1c477b01a171473ee8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754487004,
      "headline": "Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings",
      "id": 136237598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=0ca842306d09a80b48e22eae006dafe2f005372290151c1c477b01a171473ee8"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript",
    "summary": "Explore Bio-Techne's Q4 2025 earnings highlights, including 3% organic growth, strategic moves, and market trends in proteomics, cell therapy, and...",
    "url": "https://finnhub.io/api/news?id=84dc9120c3b1d52f6cd6a7b30aa5ea22bb05f9c8773b4f16f5988454bbe64128",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754484744,
      "headline": "Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript",
      "id": 136238635,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "TECH",
      "source": "SeekingAlpha",
      "summary": "Explore Bio-Techne's Q4 2025 earnings highlights, including 3% organic growth, strategic moves, and market trends in proteomics, cell therapy, and...",
      "url": "https://finnhub.io/api/news?id=84dc9120c3b1d52f6cd6a7b30aa5ea22bb05f9c8773b4f16f5988454bbe64128"
    }
  },
  {
    "ts": null,
    "headline": "Techne (TECH) Beats Q4 Earnings and Revenue Estimates",
    "summary": "Techne (TECH) delivered earnings and revenue surprises of +6.00% and +0.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=adc58245155aaec14fd5125d5b6efddf1be74929b3eb7a48b7200be6032c5e36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754481002,
      "headline": "Techne (TECH) Beats Q4 Earnings and Revenue Estimates",
      "id": 136237599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Techne (TECH) delivered earnings and revenue surprises of +6.00% and +0.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=adc58245155aaec14fd5125d5b6efddf1be74929b3eb7a48b7200be6032c5e36"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne Releases Fourth Quarter Fiscal 2025 Results",
    "summary": "Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2025.",
    "url": "https://finnhub.io/api/news?id=0c579ec766c4af5d4d4dba91673fc7f4c10356d82cdd70b9f7b3dae562b59f6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754476200,
      "headline": "Bio-Techne Releases Fourth Quarter Fiscal 2025 Results",
      "id": 136232760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TECH",
      "source": "Yahoo",
      "summary": "Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2025.",
      "url": "https://finnhub.io/api/news?id=0c579ec766c4af5d4d4dba91673fc7f4c10356d82cdd70b9f7b3dae562b59f6d"
    }
  }
]